TEGRETOL-XR (carbamazepine) by Novartis is cytochrome p450 3a4 inducers [moa]. First approved in 1996.
Drug data last refreshed 3d ago
TEGRETOL-XR (carbamazepine) is an extended-release oral tablet and CYP3A4 inducer used to treat epilepsy, bipolar disorder, and seizures. It functions as a mood stabilizer and anticonvulsant, with a mechanism of action involving inhibition of voltage-gated sodium channels. The drug has been approved since 1996 and remains a foundational therapy across multiple CNS indications.
Product approaching loss of exclusivity with moderate competitive pressure (score: 30/100); commercial teams are likely focused on cost defense and brand loyalty strategies rather than growth.
Cytochrome P450 3A4 Inducers
Mood Stabilizer
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Drug-drug Interaction Trial of AP31969 and Carbamazepine or Itraconazole
A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together
A Study to Learn How Fluconazole, Carbamazepine and Itraconazole Affect How the Body Processes ASP3082 in Healthy Adults
To Assess the Enzyme Inducing Effects of Carbamazepine on the PK of Mirdametinib in Healthy Participants
A Study to Learn if Multiple Doses of the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine PF-07248144
Worked on TEGRETOL-XR at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on TEGRETOL-XR offers exposure to mature-market brand management, generic defense strategies, and cost optimization—valuable for professionals seeking to transition into managed-care negotiation or lifecycle extension roles. However, the approaching loss of exclusivity and minimal clinical development signal limited growth headroom and lower strategic priority compared to peak-stage competitors.